Enzymun-Test AFP
PMA P860044
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMAAPPR | NumberP860044 | Date19 Jul 1991 | StatusActive |
Recalls
No FDA recalls found in the data synced 6 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA PMA Active
Specification
- Full name
- Enzymun-Test{r} Afp
- Generic Name
- KIT, TEST,ALPHA-FETOPROTEIN FOR TESTICULAR CANCER
- PMA Number
- FDA Product Code
- LOJ
- Device Class
- Class II
- Regulation
- 21 CFR Part 866.6010
- Advisory Committee
- Immunology
- FDA Decision
- APPR Approved
- PMA Supplement
- S002 (Normal 180 Day Track)
Overview
AI-generated summary, 18 Sep 2026
The Enzymun-Test AFP is a Kit, Test, Alpha-Fetoprotein for Testicular Cancer, classified under the FDA’s Device Class II (regulation number 866.6010). This immunoassay test detects alpha-fetoprotein (AFP) levels in serum or plasma, aiding in the diagnosis, monitoring, and management of testicular cancer and other conditions associated with elevated AFP.
This test is supplied as a single-use diagnostic kit and requires laboratory processing. It is intended for use in regulated clinical immunology settings and must be handled according to manufacturer instructions. The device is not MRI-safe and is distributed in multiple reference codes (e.g., 3002808328, 1036362) for inventory management. Authorized under FDA PMA (P860044), it adheres to FDA Class II standards for in vitro diagnostic use.
Other devices from Boehringer Mannheim Corp.
Questions
AI-generated answers, 18 Sep 2026
What clinical conditions is the Enzymun-Test AFP primarily used to evaluate or monitor?
The Enzymun-Test AFP is designed to detect alpha-fetoprotein (AFP) levels in serum or plasma, which aids in diagnosing and monitoring testicular cancer as well as other conditions linked to elevated AFP, such as certain liver diseases or germ cell tumors. It supports clinical decision-making in immunology settings by providing quantitative measurements of AFP.
Is the Enzymun-Test AFP intended for single-use or repeated testing in the same patient?
The Enzymun-Test AFP is supplied as a single-use diagnostic kit, meaning each kit is intended for one test procedure. This design ensures accuracy and sterility per manufacturer guidelines, as repeated use could compromise reliability or introduce contamination risks.
How is this test distributed, and what reference codes should buyers expect to encounter?
The Enzymun-Test AFP is distributed under multiple FDA-assigned reference codes (e.g., 3002808328, 1036362, 3007111389) to facilitate inventory management. Buyers may encounter several codes depending on the specific lot or variant, so verifying the exact code with the manufacturer or distributor is recommended for ordering.
What regulatory pathway was followed for FDA clearance of the Enzymun-Test AFP?
The Enzymun-Test AFP received FDA clearance via a Premarket Approval (PMA) under PMA number P860044, which is the regulatory route for higher-risk Class II devices. This approval ensures the test meets stringent performance and safety standards for detecting AFP in serum/plasma, particularly for testicular cancer monitoring.
Can this test be used outside a regulated clinical immunology lab, or is it strictly laboratory-only?
The Enzymun-Test AFP is intended exclusively for use in regulated clinical immunology settings, as specified in its labeling. It requires laboratory processing and adherence to manufacturer instructions, so point-of-care or non-laboratory use is not authorized. This aligns with its classification under FDA regulation 866.6010 for in vitro diagnostic use.